Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

To assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing relapsing multiple sclerosis (RMS)

  • 0 views
  • 11 Nov, 2021
  • 9 locations
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared …

gilenya
aubagio
rebif
tecfidera
ACTH
  • 187 views
  • 23 Jan, 2021
  • 4 locations
Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke

Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with AIS as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. So in …

  • 0 views
  • 01 Aug, 2021
  • 1 location
Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

The purpose of this study is to assess the efficacy of autologous PBSCT versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) for inflammatory MS failing alternate approved therapy. Disease progression, defined as a 1-point increase in the Expanded Disability Status scale (EDSS) on …

mitoxantrone
avonex
MRI
disease or disorder
betaseron
  • 120 views
  • 08 Nov, 2020
  • 1 location
COVID Vaccine Response in MS

The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to non-MS controls. We have chosen to compare DMT-treated MS patients to non-MS controls …

fingolimod
gilenya
disease or disorder
Accepts healthy volunteers
ocrelizumab
  • 0 views
  • 07 Oct, 2021